Skip to main content
Top
Published in: Sleep and Breathing 3/2008

01-08-2008 | Original Article

Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome

Authors: Burcu Oktay, Erdem Akbal, Hikmet Firat, Sadik Ardic, Ramazan Akdemir, Murat Kizilgun

Published in: Sleep and Breathing | Issue 3/2008

Login to get access

Abstract

The aim of this study was to establish cardiac damage related to nocturnal ischemia using heart type fatty acid binding protein (h-fabp), which reaches detectable levels in plasma after being released from myocytes in case of ischemia in obstructive sleep apnea syndrome (OSAS) patients without coronary artery disease (CAD). Fifty patients diagnosed with OSAS in our sleep laboratory with polysomnographic analysis (PSG), who did not have any previous history of cardiac disease and in whom CAD was ruled out with myocardium perfusion scintigraphy, were included in the study. Control group comprised 19 volunteers without history of cardiac disease and risk factors in whom OSAS was excluded with PSG analysis. Blood samples were drawn from the patients to examine h-fabp, creatine kinase (CK), creatine kinase-MB (CK-MB), aspartate aminotransferase (AST), troponin I levels before and after sleep. No significant difference was found in CK, CK-MB, AST, Troponin I, and h-fabp levels before and after sleep in patient and control groups (p > 0.05). No significant difference was found between groups in terms of CK, CK-MB, AST, and Troponin I levels before and after sleep, while a significant difference was found between them with regard to h-fabp levels before (p = 0.006) and after sleep (p = 0.022). When arithmetical mean of the fabp levels before and after sleep was taken in the patient group, it was found that mean value of h-fabp was associated with the desaturated period in sleep which was under 80% (p = 0.04). H-fabp seems to be a marker that will enable the detection of cardiac injury in the early asymptomatic period in OSAS patients before development of disease that can be detected by imaging methods. Further studies are required to investigate the relation between the value of h-fabp and the development of cardiac dysfunction in the long term.
Literature
1.
go back to reference Young T, Palta M, Dempsey J et al (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328(17):1230–1235PubMedCrossRef Young T, Palta M, Dempsey J et al (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328(17):1230–1235PubMedCrossRef
2.
go back to reference Lattimore J-DL, Celermajer DS, Wilcox I (2003) Obstructive sleep apnea and cardiovascular disease. J Am Coll Health 41:1429–1437 Lattimore J-DL, Celermajer DS, Wilcox I (2003) Obstructive sleep apnea and cardiovascular disease. J Am Coll Health 41:1429–1437
3.
go back to reference McNicholas WT, Bonsignore MR (2007) Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 29(1):156–178 (Jan)PubMedCrossRef McNicholas WT, Bonsignore MR (2007) Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 29(1):156–178 (Jan)PubMedCrossRef
4.
go back to reference Marin JM, Carrizo SJ et al (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea–hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365(9464):1046–1053 (Mar 19–25)PubMed Marin JM, Carrizo SJ et al (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea–hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365(9464):1046–1053 (Mar 19–25)PubMed
5.
go back to reference Parish JM, Somers VK (2004) Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc 79(8):1036–1046 (August)PubMed Parish JM, Somers VK (2004) Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc 79(8):1036–1046 (August)PubMed
6.
go back to reference Andreas S, Schultz R, Werner GS, Kreuzer H (1996) Prevalence of obstructive sleep apnea in patients with coronary artery disease. Coron Artery Dis 7:541–545PubMedCrossRef Andreas S, Schultz R, Werner GS, Kreuzer H (1996) Prevalence of obstructive sleep apnea in patients with coronary artery disease. Coron Artery Dis 7:541–545PubMedCrossRef
7.
go back to reference Peled N, Abinader EG, Pillar G, Sharif D, Lavie P (1999) Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment. J Am Coll Cardiol 34(6):1744–1749 (Nov 15)PubMedCrossRef Peled N, Abinader EG, Pillar G, Sharif D, Lavie P (1999) Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment. J Am Coll Cardiol 34(6):1744–1749 (Nov 15)PubMedCrossRef
8.
go back to reference Hanly P, Sasson Z et al (1993) ST-segment depression during sleep in obstructive sleep apnea. Am J Cardiol 71(15):1341–1345PubMedCrossRef Hanly P, Sasson Z et al (1993) ST-segment depression during sleep in obstructive sleep apnea. Am J Cardiol 71(15):1341–1345PubMedCrossRef
9.
go back to reference Alhadi HA, Fox KA (2004) Do we need additional markers of myocyte necrosis: the potential value of heart fatty acid binding protein. Q J Med 97:187–198 Alhadi HA, Fox KA (2004) Do we need additional markers of myocyte necrosis: the potential value of heart fatty acid binding protein. Q J Med 97:187–198
10.
go back to reference Nakata T et al (2003) Human Heart type fatty acid binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology 99:96–104PubMedCrossRef Nakata T et al (2003) Human Heart type fatty acid binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology 99:96–104PubMedCrossRef
11.
go back to reference Schafer H, Koehier U, Ploch T et al (1997) Sleep related myocardial ischemia and sleep structure in patients with obstructive sleep apnea and coronary heart disease. Chest 111:387–393PubMedCrossRef Schafer H, Koehier U, Ploch T et al (1997) Sleep related myocardial ischemia and sleep structure in patients with obstructive sleep apnea and coronary heart disease. Chest 111:387–393PubMedCrossRef
12.
go back to reference Alonso-Fernández A, García-Río F et al (2005) Cardiac rhythm disturbances and ST-segment depression episodes in patients with obstructive sleep apnea–hypopnea syndrome and its mechanisms. Chest 127:15–22PubMedCrossRef Alonso-Fernández A, García-Río F et al (2005) Cardiac rhythm disturbances and ST-segment depression episodes in patients with obstructive sleep apnea–hypopnea syndrome and its mechanisms. Chest 127:15–22PubMedCrossRef
13.
go back to reference Andreas S, Hajak G, Natt P et al (1991) ST segmental changes and arrhythmias in obstructive sleep apnea. Pneumologie 45(9):720–724PubMed Andreas S, Hajak G, Natt P et al (1991) ST segmental changes and arrhythmias in obstructive sleep apnea. Pneumologie 45(9):720–724PubMed
14.
go back to reference Hanly P, Sasson Z, Zuberi N et al (1993) ST-segment depression during sleep in obstructive sleep apnea. Am J Cardiol 71:1341–1345PubMedCrossRef Hanly P, Sasson Z, Zuberi N et al (1993) ST-segment depression during sleep in obstructive sleep apnea. Am J Cardiol 71:1341–1345PubMedCrossRef
15.
go back to reference Franklin KA, Nilsson JB, Sahlin C et al (1995) Sleep apnoea and nocturnal angina. Lancet 345:1085–1087PubMedCrossRef Franklin KA, Nilsson JB, Sahlin C et al (1995) Sleep apnoea and nocturnal angina. Lancet 345:1085–1087PubMedCrossRef
16.
go back to reference Gami AS, Svatikova A, Wolk R et al (2004) Cardiac troponin T in obstructive sleep apnea. Chest 125(6):2097–2100PubMedCrossRef Gami AS, Svatikova A, Wolk R et al (2004) Cardiac troponin T in obstructive sleep apnea. Chest 125(6):2097–2100PubMedCrossRef
17.
go back to reference Pepin JL, Levy P (2002) Pathophysiology of cardiovascular risk in sleep apnea syndrome (SAS). Rev Neurol (Paris) 158(8–9):785–797 Pepin JL, Levy P (2002) Pathophysiology of cardiovascular risk in sleep apnea syndrome (SAS). Rev Neurol (Paris) 158(8–9):785–797
18.
go back to reference Narkiewicz K, Somers VK (2003) Sympathetic nerve activity in obstructive sleep apnea. Acta Physiol Scand 177:385–390PubMedCrossRef Narkiewicz K, Somers VK (2003) Sympathetic nerve activity in obstructive sleep apnea. Acta Physiol Scand 177:385–390PubMedCrossRef
19.
go back to reference Somers VK, Dyken ME, Clary MP, Abboud FM (1995) Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96:1897–904PubMedCrossRef Somers VK, Dyken ME, Clary MP, Abboud FM (1995) Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96:1897–904PubMedCrossRef
20.
go back to reference Aydin M, Altin R (2004) Cardiac autonomic activity in obstructive sleep apnea. Tex Heart Inst J 31(2):132–136PubMed Aydin M, Altin R (2004) Cardiac autonomic activity in obstructive sleep apnea. Tex Heart Inst J 31(2):132–136PubMed
21.
go back to reference Noda A, Ito R, Okada T et al (1998) Twenty-four-hour ambulatory oxygen desaturation and electrocardiographic recording in obstructive sleep apnea syndrome. Clin Cardiol 21(7):506–510 (Jul)PubMed Noda A, Ito R, Okada T et al (1998) Twenty-four-hour ambulatory oxygen desaturation and electrocardiographic recording in obstructive sleep apnea syndrome. Clin Cardiol 21(7):506–510 (Jul)PubMed
22.
go back to reference Yoshimoto K, Tanaka T, Somiya K et al (1995) Human heart-type cytoplasmic fatty acid-binding protein as an indicator of acute myocardial infarction. Heart Vessels 10:304–309PubMedCrossRef Yoshimoto K, Tanaka T, Somiya K et al (1995) Human heart-type cytoplasmic fatty acid-binding protein as an indicator of acute myocardial infarction. Heart Vessels 10:304–309PubMedCrossRef
23.
go back to reference Zschiesche W, Kleine AH, Spitzer E, Veerkamp JH, Glatz JF (1995) Histochemical localization of heart-type fatty acid-binding protein in human and murine tissues. Histochem Cell Biol 103:147–156PubMedCrossRef Zschiesche W, Kleine AH, Spitzer E, Veerkamp JH, Glatz JF (1995) Histochemical localization of heart-type fatty acid-binding protein in human and murine tissues. Histochem Cell Biol 103:147–156PubMedCrossRef
24.
go back to reference Azzazy HME, Pelsers MMAL, Christenson RH (2006) Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem 52:19–29PubMedCrossRef Azzazy HME, Pelsers MMAL, Christenson RH (2006) Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem 52:19–29PubMedCrossRef
25.
go back to reference Gorski J, Hermens WT, Borawski J, Mysliwiec M, Glatz JF (1997) Increased fatty acid-binding protein concentration in plasma of patients with chronic renal failure. Clin Chem 43:193–195PubMed Gorski J, Hermens WT, Borawski J, Mysliwiec M, Glatz JF (1997) Increased fatty acid-binding protein concentration in plasma of patients with chronic renal failure. Clin Chem 43:193–195PubMed
26.
go back to reference Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K (1991) Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 24:195–201PubMedCrossRef Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K (1991) Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 24:195–201PubMedCrossRef
27.
go back to reference Wodzig KW, Pelsers MM, Van der Vusse GJ, Roos W, Glatz JF (1997) One-step enzyme-linked immunosorbent assay (ELISA) for plasma fatty acid-binding protein. Ann Clin Biochem 34:263–268PubMed Wodzig KW, Pelsers MM, Van der Vusse GJ, Roos W, Glatz JF (1997) One-step enzyme-linked immunosorbent assay (ELISA) for plasma fatty acid-binding protein. Ann Clin Biochem 34:263–268PubMed
28.
go back to reference Tsuji R, Tanaka T, Sohmiya K et al (1993) Human heart-type cytoplasmic fatty acid-binding protein in serum and urine during hyperacute myocardial infarction. Int J Cardiol 41:209–217PubMedCrossRef Tsuji R, Tanaka T, Sohmiya K et al (1993) Human heart-type cytoplasmic fatty acid-binding protein in serum and urine during hyperacute myocardial infarction. Int J Cardiol 41:209–217PubMedCrossRef
29.
go back to reference Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ (1992) Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 116:155–162PubMedCrossRef Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ (1992) Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 116:155–162PubMedCrossRef
30.
go back to reference Ohkura Y, Asamaya K, Ishii H et al (1995) Development of sandwich enzyme-linked immunosorbent assay fort he determination of human heart type fatty acid-binding protein in plazma and urine by using two different monoclonal antibodies specific for human heart fatty acid binding protein. J Immunol Methods 178:99–111CrossRef Ohkura Y, Asamaya K, Ishii H et al (1995) Development of sandwich enzyme-linked immunosorbent assay fort he determination of human heart type fatty acid-binding protein in plazma and urine by using two different monoclonal antibodies specific for human heart fatty acid binding protein. J Immunol Methods 178:99–111CrossRef
Metadata
Title
Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome
Authors
Burcu Oktay
Erdem Akbal
Hikmet Firat
Sadik Ardic
Ramazan Akdemir
Murat Kizilgun
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
Sleep and Breathing / Issue 3/2008
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-007-0167-1

Other articles of this Issue 3/2008

Sleep and Breathing 3/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.